Human immunodeficiency virus, type 1 Nef disrupts viral antigen presentation and promotes viral immune evasion from cytotoxic T lymphocytes. There is evidence that Nef acts early in the secretory pathway to redirect major histocompatibility complex class I (MHC-I) from the trans-Golgi network to the endolysosomal pathway. However, a competing model suggests that Nef acts much later by accelerating MHC-I turnover at the cell surface. Here we demonstrate that Nef targets early forms of MHC-I molecules in the endoplasmic reticulum by preferentially binding hypophosphorylated cytoplasmic tails. The Nef-MHC-I complex migrates normally into the Golgi apparatus but subsequently fails to arrive at the cell surface and become phosphorylated. Cell type-specific differences in the rate of MHC-I transport through the secretory pathway correlate with responsiveness to Nef and co-precipitation of adaptor protein 1 with the Nef⅐MHC-I complex. We propose that the assembly of a Nef⅐MHC-I⅐adaptor protein 1 complex early in the secretory pathway is important for Nef activity.
Antigenic peptides are produced in the cytoplasm of almost all cell types by the proteasome and are transported into the endoplasmic reticulum (ER) where they assemble with the MHC-I heavy and light chains. The trimeric complex is formed with the assistance of a number of protein chaperones and, once properly folded, exits the ER to the Golgi apparatus. Ultimately, the peptide-loaded MHC-I arrive on the cell surface to display their antigens to CTLs (11) . To combat the anti-viral immune response, some viruses have developed strategies to disrupt antigen presentation and to thereby prevent CTL recognition of infected target cells (12) . Indeed, expression of the HIV-1 Nef protein protects infected cells from CTL-mediated lysis in vitro by reducing the cell surface expression of MHC-I HLA-A and B allotypes (13) (14) (15) (16) (17) (18) . In addition, recent studies using in vivo model systems demonstrated that the effects of Nef on MHC-I cell surface expression are important for HIV disease pathogenesis (19, 20) .
There has been progress in our understanding of how Nef reduces MHC-I cell surface expression; however, many questions remain. To disrupt MHC-I trafficking, Nef interacts with the MHC-I cytoplasmic tail (21) , a highly conserved 33-amino acid domain with 9 conserved serine residues, some of which are phosphorylated in vivo (22) . Nef does not affect MHC-I protein synthesis or transport into the medial Golgi apparatus (23) but causes MHC-I to accumulate in a juxtanuclear compartment in Nef-expressing cells (18, 24) . Based on data collected in non-T cell lines, it was thought that Nef reduced MHC-I cell surface expression by accelerating endocytosis and promoting retrograde transport of internalized MHC-I to the trans-Golgi network (TGN) (18, 23, 24) . However, more recent experiments that directly compared MHC-I trafficking in Nefexpressing T cells and HeLa cells have since revealed that Nef behaves differently in T cells (25) . In T cells, the predominant effect of Nef is to disrupt transport of MHC-I from the secretory pathway to the cell surface, and this results in a more dramatic effect of Nef on MHC-I cell surface expression.
Recent data has indicated that the adaptor protein, AP-1, is necessary for Nef to disrupt MHC-I trafficking (26) . AP-1 is a heterotetrameric protein complex that sorts proteins by binding recognition sequences in cytoplasmic tails and linking them to clathrin. In this manner, proteins are directed from the TGN into the endolysosomal pathway. Nef targets MHC-I from the TGN to the lysosomes for degradation by promoting a physical interaction between AP-1 and the cytoplasmic tail of MHC-I (26) . However, it is not known why this pathway is more active in T cells than other cell types.
We now present evidence that in T cells, Nef targets MHC-I early in the biosynthetic pathway by preferentially binding newly synthesized hypophosphorylated MHC-I. Nef then prevents MHC-I from reaching the cell surface and becoming phosphorylated. We have found that the capacity for Nef to recruit AP-1 and disrupt MHC-I trafficking is cell type-dependent. In HeLa cells, a more rapid rate of MHC-I maturation through the secretory compartment appears to limit the ability of the Nef⅐MHC-I complex to bind AP-1. Reducing the rate of MHC-I maturation by incubating these cells at a lower temperature rescues Nef activity and promotes AP-1 recruitment to the MHC-I cytoplasmic tail. By binding newly synthesized MHC-I early in the secretory pathway, Nef targets the MHC-I most likely to harbor viral antigenic peptides.
MATERIALS AND METHODS

Preparation of Cell Lines
Expressing HLA-A2 Mutants-The construction of TM1, TM2, TM3, and TM4 has been described previously (27) . The combined mutant TM1,4 was made by PCR mutagenesis using the TM4 primers with TM1 as a template (27) . Then TM1,4 was used as a template to make the triple mutants TM1,2,4 using the following mutant primers: TM124 -5Ј (5Ј-GCAGATAGAAAAGGAGG-GGCCTACGCCCAGGCTGCAAGCAGTGAC-3Ј) and TM124 -3Ј (5Ј-G-TCACTGCTTGCAGCCTGGGCGTAGGCCCCTCCTTTTCTATCTGC-3Ј). TM2E and TM3E were constructed by PCR mutagenesis using wild type HLA-A2 as a template with the following mutant primers: TM2E-5Ј (5Ј-GCTCAGATAGAAAAGGAGGGGAGTACGAGCAGGCT-GCAAGCAGTGAC-3Ј), TM2E-3Ј (5Ј-GTCACTGCTTGCAGCCTGCT-CGTACTCCCCTCCTTTTCTATCTGAGC-3Ј), TM3E-5Ј (5Ј-GCTACT-CTCAGGCTGCAAGCGAGGACGAGGCCCAGGGCTCTGATGTG-3Ј), and TM3E-3Ј (5Ј-CACATCAGAGCCCTGGGCCTCGTCCTCGCTTGC-AGCCTGAGAGTAGC-3Ј). Each PCR product was cloned into the murine stem cell virus retroviral vector (28) , packaged into retrovirus (29) , and introduced into CEM T cells or HeLa cells, and the cell lines were selected in neomycin (1 mg/ml). HeLa cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM glutamine, 10% fetal bovine serum (FBS), penicillin, and streptomycin. CEM-SS lines were maintained in RPMI medium supplemented with 10 mM HEPES, 2 mM glutamine, 10% FBS, penicillin, and streptomycin.
Preparation of Primary T Cells-HLA-A2 ϩ PBMCs were purified from buffy coats obtained from the Lansing Red Cross as previously described (13) . Nonadherent cells were used within 24 h for pulse-chase assays or were phytohemagglutinin-activated and HIV-infected as previously described (13) .
Antibodies-The monoclonal antibodies BB7.2 and HC10, which specifically recognizes the HLA-A2 allotype of MHC-I (30) and unfolded MHC-I (31), respectively, were purified from ascites using a Hitrap protein A FF column according to the manufacturer's instructions (Amersham Biosciences). The antibody directed at placental alkaline phosphatase (PLAP) was obtained from Biomeda. The AG11 HIV-1 Nef antibody (32) for Western blotting was obtained from Dr. James Hoxie. HA-HLA-A2 was detected using the anti-HA antibody HA.11 (Covance). The pasta-1 antibody was obtained from Peter Cresswell (33) . The 1 adaptin subunit of AP-1 was detected using RY/1 (1:2500, from Dr. Linton Traub). The antibody to the ␥-adaptin subunit of AP-1 was purchased from BD Biosciences. The ␤ 2 m antibody was purchased from DAKO. The secondary antibodies used in this study were goat antimouse immunoglobulin G-phycoerythrin (Caltag) for HLA-A2 stains and goat anti-rabbit-fluorescein isothiocyanate (Caltag) for PLAP stains. Goat anti-mouse horseradish peroxidase (Zymed Laboratories Inc.) and goat anti-mouse anti-IgG 1 heavy chain (Zymed Laboratories Inc.) were used for Western blotting.
Viral Transduction of CEM T Cells and HeLa Cells-A replicationdefective adenoviral vector expressing HIV-1 NL4 -3 Nef (Adeno-Nef) and lacking the entire E3 region (including E3/19k, 27925-30954) was made by the University of Michigan Vector Core by recombining the cosmid cAd5.dlE3 with a Nef-containing shuttle plasmid by a Cre-Lox reaction (21, 25, 34) . The control virus (control-adeno) was identical to adeno-Nef except that it lacked the Nef open reading frame. Adenovirus transductions were performed as follows: HeLa cells or T cells were incubated with adenovirus in DMEM or RPMI supplemented with 2% FBS. After 2 h, an equal volume of fresh DMEM or RPMI plus 10% FBS was added. The cells were then incubated for 24 to 72 h prior to harvest. CEM T cells were less susceptible to adenoviral transduction than HeLa cells; equivalent Nef levels required an MOI of 10,000:1 for CEM T cells compared with an MOI of 100:1 for HeLa cells (based on 293 cell infectivity) (25) . However, CEM T cells were much more susceptible to Nef, and therefore an MOI of 100:1 resulted in a 2-fold decrease in MHC-I surface expression in HeLa cells compared with a 5-10-fold decrease in CEM T cells. For HIV transductions, primary T cells were treated as previously described (13) . CEM T cells were treated with 1 ml of high titer HXB-EP (13, 35) pseudotyped with VSV-G protein and analyzed for MHC-I expression after 72 h. This HIV molecular clone contains the marker gene PLAP inserted into the envelope open reading frame and expresses levels of Nef equivalent to that of unmodified HIV molecular clones (13, 36) . The PLAP marker was used to monitor infection rate, which was usually greater than 90% (25) .
Analysis (21), except that the immune complexes were washed with radioimmunoprecipitation assay buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride). The precipitated samples were then digested with endo H according to the manufacturer's protocol (New England Biolabs), separated by SDS-PAGE, and quantified using a PhosphorImager with Image Quant software.
Transport Assay-The ability of Nef to disrupt transport of HLA-A2 was measured as previously described (37) . Briefly, 6 ϫ 10 6 transduced CEM T cells or 5 ϫ 10 5 HeLa cells (plated on day one, transduced with adeno-Nef on day 2, and harvested on day 4) were pulse-labeled as described above and incubated for the indicated chase period in PBS plus 0.5 mg/ml cell-impermeable biotinylation reagent (NHS-biotin; Pierce). The reaction was quenched in 25 mM lysine according to the manufacturer's protocol. HLA-A2 was immunoprecipitated as described above except that the precipitated sample was eluted from the beads by boiling for 10 min in 10% SDS. One-third of the eluate was collected to examine total HLA-A2 levels, and the remaining two-thirds were diluted and reprecipitated with avidin-agarose beads (CalBiochem) to capture HLA-A2 that had been transported to the cell surface and biotinylated (25) . The samples were analyzed by SDS-PAGE and quantified using a PhosphorImager with Image Quant software.
Phosphate Labeling-5 ϫ 10 6 CEM T cells were transduced with the indicated MOI of adenovirus. The cells were washed with PBS, preincubated for 30 min in DMEM or RPMI phosphate-free medium plus 10% dialyzed FBS, and labeled with 0.5 mCi/ml of [ 32 P]orthophosphate (PerkinElmer Life Sciences) for 4 h. The cells were then lysed in Nonidet P-40 lysis buffer, and HLA-A2 was immunoprecipitated as described above. The samples were analyzed by SDS-PAGE and quantified using a PhosphorImager with Image Quant software.
Co-precipitation Assays-The protocol used to detect Nef binding has been described previously (21) . Briefly, 7.5 ϫ 10 5 HeLa cells (plated the day before) or 5 ϫ 10 6 CEM T cells were transduced with the indicated MOI of adenovirus. Alternatively, 10 ϫ 10 6 primary T cells were transduced with HXB-EP and grown for 3 days. Four hours prior to harvest, the cells were incubated in 25 mM NH 4 Cl. The cells were then washed with PBS, treated with the reversible cross-linker DTBP (Pierce), and lysed in PBS, 0.3% Chaps, 0.1% SDS, pH 8, 1 mM phenylmethylsulfonyl fluoride. One percent of the lysates (normalized for total protein) were set aside for input controls, and the remainder was precleared over night with protein A/G-agarose (Oncogene). The lysates were then immunoprecipitated for 2 h with pasta-1 or BB7.2 beads, washed six times in Tris-buffered saline, 0.3% Chaps, 0.1% SDS, and eluted in 150 mM dithiothreitol at 37°C for 30 min. The presence of co-precipitating Nef or HA-HLA-A2 was detected by immunoblot using an antibody against Nef (AG11, 1:500 (32) from Dr. James Hoxie) or HA-HLA-A2 (Covance) and goat anti-mouse IgG 1 horseradish peroxidase (Zymed Laboratories Inc., 1:50,000). Co-precipitating AP-1 was detected using an antibody against the ␥-adaptin subunit of AP-1(1:100) and goat anti-rabbit horseradish peroxidase (Zymed Laboratories Inc., 1:50,000). Input controls were mock eluted in 150 mM dithiothreitol at 37°C for 30 min and analyzed by Western blot as described above except that the secondary antibody was used at a higher dilution (1:200,000).
For analysis of Nef bound to surface MHC-I, the binding was performed as described above except that 2 ϫ 10 7 transduced CEM T cells were incubated in a cell impermeable NHS-biotin (Pierce) solution in PBS to label cell surface proteins and then washed in 25 mM lysine after cross-linker treatment. In addition, the lysates were immunoprecipitated with anti-HA affinity matrix beads (Roche Applied Science), washed, and eluted with HA peptide (Roche Applied Science) for 30 min at 37°C. A fraction of the eluate was collected and saved to examine Nef co-precipitation with total HA-A2. A fraction was reprecipitated with BB7.2 beads. The remainder was reprecipitated with avidin-agarose beads to capture HA-A2 that had been transported to the cell surface and biotinylated. Sample volumes were adjusted with a goal to precipitate similar amounts of HA-A2. All of the samples were washed three times in Tris-buffered saline, 0.3% Chaps, 0.1% SDS, pH 8, 1 mM phenylmethylsulfonyl fluoride, eluted in 150 mM dithiothreitol at 37°C for 30 min, and analyzed by Western blot as described above. Densitometry was performed on scanned images using Image Quant 5.2 software.
RNA Interference Treatment-The following duplex siRNAs (Ambion) were used in this study: siGFP (sense, 5Ј-GCUGACCCUGAAGU-UCAUCTT-3Ј; antisense, 5Ј-GAUGAACUUCAGGGUCAGCTT-3Ј) and si␤ 2 m (sense, 5Ј-GGUUUACUCACGUCAUCCATT-3Ј; antisense, 5Ј-UGGAUGACGUGAGUAAACCTG-3Ј).
The 1A siRNA has been previously described (38) . Astrocytoma (373mg) or HeLa cells were transfected with annealed duplex siRNAs using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. Briefly, on day 1, the cells were plated onto 6-well plates (1 ϫ 10 5 cells/well). On day 2, each well was transfected using 0.16 nmol of siRNA and 4 l of Lipofectamine 2000 reagent. On day 3, the cells were replated onto 6-well plates (1 ϫ 10 5 cells/well), and on day 4 they were transfected a second time. Four to six hours after the second siRNA transfection, the medium was removed, and the cells were transduced with adenovirus (MOI of 50:1). The cells were harvested and analyzed 24 h post-transduction.
For experiments using CEM T cells, the cells were first transduced with adenovirus (MOI of 100:1). Twenty-four hours later, 5 ϫ 10 6 cells were electroporated with 1 nmol of siRNA according to the manufacturer's protocol (Amaxa Biosystems). The cells were then incubated for 48 h before analysis.
Immunofluorescence Microscopy-373 cells were grown on 8-well chambered glass slides and were transduced with adeno-Nef at an MOI of 300. Twenty-four hours post-transduction, the cells were fixed in methanol:acetone (1:1) for 2 min at room temperature. The cells were washed with wash buffer (PBS, 10 mM HEPES, 2% goat serum, 0.025% sodium azide) and blocked in wash buffer (supplemented with 10% human serum and 10% goat serum). The cells were first stained with a monoclonal antibody for tapasin (pasta-1, 1:100, (33)), followed by secondary staining with goat anti-mouse IgG1 AlexaFluor 488 (Molecular Probes; 1:250). The cells were then incubated in wash buffer supplemented with 10% mouse serum overnight. Nef was detected by first staining with a biotinylated anti-Nef antibody (AG11, 20 g/ml) followed by staining with NeutrAvidin-Texas Red (Molecular Probes, 1:400). The AG11 antibody was biotinylated with NHS-biotin (Pierce) according to the manufacturer's protocol. Glass coverslips were mounted using Prolong Antifade kit (Molecular Probes). Single Z sections were collected using a Zeiss LSM 510 confocal microscope, and the images were processed using Adobe Photoshop 6.0 software.
RESULTS
The Effect of Nef on MHC-I Phosphorylation-MHC-I is phosphorylated on its cytoplasmic tail late in its biosynthesis after it has reached the TGN (39 -41) . Because there is evidence that Nef affects MHC-I trafficking after it has reached the TGN, we asked whether Nef expression affected MHC-I phosphorylation. To test this, T cells transduced with a replication-defective adenoviral vector expressing Nef or a control adenoviral vector were metabolically labeled with [ 32 P]orthophosphate, and MHC-I HLA-A2 was immunoprecipitated. As shown in Fig. 1 (lanes 3 and 4) , MHC-I was indeed phosphorylated in T cells, and as expected, all of the phosphorylated MHC-I was endo H-resistant (i.e. it had migrated into the medial Golgi apparatus and undergone trimming of mannose residues rendering it resistant to cleavage by endo H). In contrast, ϳ50% of newly synthesized HLA-A2 was endo H-resistant after a 4-h continuous labeling with 35 S-labeled amino acids (Fig. 1) . Mutation of key serine residues in the cytoplasmic tail ( Fig. 2A ; tail mutant; TM1,2,4) dramatically reduced phosphorylation of MHC-I, confirming that MHC-I phosphorylation occurred on its cytoplasmic tail (Fig. 1) . Finally, we demonstrated that expression of Nef resulted in a 10-fold decrease in MHC-I phosphorylation (Fig. 1, compare lanes 3 and 4 with  lanes 5 and 6) .
The role of Phosphorylation on MHC-I Trafficking in Nefexpressing Cells-To further explore the role of cytoplasmic tail phosphorylation in MHC-I trafficking, we examined the effect of mutating potential phosphorylation sites on MHC-I transport and cell surface expression. This was accomplished by systematically mutating each serine residue to alanine in pairs (TM1, TM2, TM3, and TM4 in Fig. 2A ) (27) . In addition, we constructed combined mutants (TM1,2,4 and TM1,3,4) and phosphorylation "mimics" in which glutamic acid residues were substituted for serines (TM2E and TM3E in Fig. 2A) .
Each mutant was expressed on the surface of T cells at levels similar to wild type HLA-A2 (Fig. 2C, red curves) and matured through the secretory compartment at similar rates (data not shown and Fig. 3A) . To assess whether these mutations affected susceptibility to Nef, each cell line was transduced separately with a replication-defective adenoviral vector expressing Nef (adeno-Nef) and an HIV molecular clone that expressed Nef under its normal regulatory elements (36) . We found that serine to alanine mutations adjacent to the tyrosine residue required for Nef binding (TM2 and TM1,2,4) were more responsive to Nef, whereas a phosphorylation mimic in this region (TM2E) responded poorly (Fig. 2, B and C) . Serine to alanine or serine to glutamic acid substitutions adjacent to the required aspartic acid (TM3) also disrupted Nef activity, indicating that this region was sensitive to different types of amino acid substitutions. In contrast, we observed no significant effect of serine to alanine substitutions at other positions (TM1 and TM4). These data provide evidence that phosphorylation adjacent to the Nef-binding site could affect Nef activity.
To determine whether changes in the phosphorylation state of the MHC-I cytoplasmic tail might affect Nef binding, we asked whether Nef co-precipitated with these mutants. As shown in Fig. 2D , more Nef co-precipitated with the hypophosphorylated mutant TM1,2,4, and less co-precipitated with the phosphorylation mimic TM2E. As a control, we included an HLA-A2 mutant, which is known to be defective at Nef binding (Y320A; Fig. 2A ). Finally, we also found that mutations in the TM3 region that inhibited the ability of Nef to reduce MHC-I surface expression reduced the amount of co-precipitating Nef protein (Fig. 2D) .
We then asked whether phosphorylation of the MHC-I cytoplasmic tail affected the ability of Nef to alter MHC-I trafficking to the cell surface or its internalization at the cell surface. As shown in Fig. 3A , mutations in cytoplasmic tail serines did not alter transport through the medial Golgi apparatus. However, they did alter the ability of Nef to decrease transport from the TGN to the cell surface (Fig. 3B) . Mimicking hypophosphorylation (TM1,2,4) stimulated this Nef activity, whereas mimicking phosphorylation (TM2E) inhibited it (8.1 versus 1.1-fold reduction respectively). In contrast, these mutations did not affect MHC-I turnover at the cell surface, which was a comparatively small effect of Nef in T cells (Ref. 25 and data not shown).
In sum, these data suggest that Nef disrupts the trafficking of MHC-I in T cells by preferentially binding hypophosphorylated MHC-I, which is found early in the secretory pathway. MHC-I is then transported normally into the medial Golgi apparatus but is blocked in its transport to the cell surface, where it would normally be phosphorylated.
Nef Does Not Co-precipitate with Cell Surface MHC-I-If this model is correct, we predicted that Nef should be unable to bind MHC-I once it has arrived at the cell surface and become phosphorylated. To test this, we labeled cell surface proteins with biotin and then immunoprecipitated first with an anti-HA antibody to isolate total HA-tagged HLA-A2 (HA-A2) (26) and then reprecipitated with an anti-HLA-A2 antibody (BB7.2) or with avidin. As expected, we found that Nef co-precipitated with total cellular HA-A2 (Fig. 4, lane 2) , and these complexes were still detectable after a second immunoprecipitation with BB7.2 (Fig.  4, lane 4) . However, Nef did not co-precipitate with HA-A2 that had been reprecipitated with avidin beads (i.e. the cell surface fraction of HLA-A2) (Fig. 4, lanes 6 and 7) . Thus, Nef appears to preferentially bind intracellular forms of HLA-A2.
Nef Binds MHC-I Early in the Secretory Pathway-To determine where in the secretory pathway Nef interacts with HLA-A2, we immunoprecipitated immature MHC-I (i.e. MHC-I that had not yet associated with the light chain ␤ 2 m) with the heavy chain-specific monoclonal antibody HC10 (31) . The HLA-A2 that immunoprecipitated with this antibody was sensitive to endo H and also co-precipitated Nef (Fig. 5A, lane 3) . These data suggest that Nef may initially bind MHC-I in the ER or early Golgi.
To further define where Nef binding occurred, we asked whether MHC-I associated with the ER resident chaperone
FIG. 2. Mutation of the MHC-I cytoplasmic tail serines affects the ability of Nef to disrupt MHC-I trafficking.
A, HLA-A2 cytoplasmic tail sequence and location of serine mutations. Mutation of the underlined amino acids was previously shown to disrupt Nef activity (17, 18, 21) . Optimal Nef binding requires the underlined tyrosine residue but not the aspartic acid (21) . B and C, T cells expressing the indicated HLA-A2 molecules were treated with HIV (B) or a replication-defective adenoviral vector expressing Nef at an MOI of 100:1. The cells were assayed after 3 days for HLA-A2 expression using flow cytometry, as described under "Materials and protein, tapasin, could co-precipitate Nef. As shown in Fig. 5 (A,  lane 4, and B, lane 3) , Nef co-precipitated with pasta-1, a monoclonal antibody directed at tapasin (33) . To ensure that co-precipitation of Nef with tapasin was specific, we demonstrated that a Nef mutant (⌬␣hx) that does not affect MHC-I cell surface expression (42) and does not co-precipitate with MHC-I (43) also did not co-precipitate with tapasin (Fig. 5C,  lanes 6 and 7) .
To demonstrate that co-precipitation of Nef with tapasin was mediated by MHC-I, we knocked out expression of the MHC-I light chain ␤ 2 m, which is required for tapasin to bind MHC-I. As predicted, we found that reducing ␤ 2 m expression diminished the interaction between tapasin and MHC-I in 373mg cells (Fig. 5D, compare lanes 1 and 2 with lanes 4 and 5) and CEM T cells (Fig. 5E, compare lane 2 with lane 3) . Correspondingly, we found that reducing ␤ 2 m expression reduced the amount of Nef co-precipitating with tapasin (Fig. 5, D 2 with lane 3) . In contrast, knocking down expression of ␤ 2 m increased the amount of free MHC-I heavy chain immunoprecipitable by HC10 and correspondingly increased the amount of co-precipitating Nef (Fig. 5F ). These data suggest that Nef is capable of binding forms of MHC-I found in the ER (free heavy chains and MHC-I molecules bound to tapasin). Consistent with this, we also found that Nef and tapasin partially co-localized with one another by confocal immunofluorescent microscopy (supplemental Fig. 1) .
Cell Type-specific Effects of Nef on MHC-I Trafficking-The effects of Nef on MHC-I trafficking are very apparent in T cells. However, in other cell types, Nef is much less active (25) . Because Nef initially binds MHC-I early in the secretory pathway, we asked whether there were cell type-specific differences in MHC-I trafficking through the early secretory pathway that could explain these differences. Interestingly, we found that in HeLa cells, HLA-A2 acquired endo H resistance more rapidly 6 and 7) . Sample volumes were adjusted in an attempt to load comparable amounts of HA-A2 on the gel. Co-precipitating Nef and HA-A2 were detected by Western blot. Relative Nef and HA-A2 recovery was determined by densitometry as described under "Materials and Methods." Ctrl denotes CEM T cells that do not express HA-A2. The results were similar in two independent experiments. than in primary T cells and CEM T cells (Fig. 6A) .
To determine whether the rate of MHC-I transport was important for Nef activity, we asked whether reducing transport rate in HeLa cells rescued the ability of Nef to function efficiently. Interestingly, we found that inserting serine to alanine mutations in the MHC-I cytoplasmic tail (TM1,2,4) and incubating the cells at 26°C both delayed the maturation of HLA-A2 in HeLa cells (Fig. 6A) . Moreover, the combined effect of tail mutations plus temperature reduction resulted in a marked delay of MHC-I transport (Fig. 6A) . Under these conditions, we also noted a dramatic increase in the ability of Nef to disrupt MHC-I trafficking (Fig. 6B) . Indeed, the reduction in MHC-I cell surface expression (19.4-fold) was very similar to what occurred when Nef was expressed in T cells. These data suggested that the reason Nef functioned more efficiently in T cells was because a crucial rate-limiting step occurred in the secretory pathway, and slower transport rates allowed this to happen more efficiently. (In T cells, we did not observe a significant effect of TM1,2,4 on transport rate (Fig. 3A) , probably because the normal rate of HLA-A2 transport was already quite slow.)
Temperature reduction and mutations in the MHC-I cytoplasmic tail, which augmented Nef activity, did not significantly affect Nef-dependent MHC-I surface instability (Fig. 6C) , which is more apparent in HeLa cells than in T cells (25) . In contrast, these changes dramatically augmented the effect of Nef on MHC-I trafficking to the cell surface (Fig. 6D) . Moreover, the effect of Nef was greater the more the transport rate was re- The results were similar in two independent experiments. C, the N-terminal ␣-helical domain of Nef is required for co-precipitation of Nef and tapasin. CEM-A2 cells were transduced with adenovirus and incubated for 3 days. Nef binding was then assessed by immunoprecipitating tapasin (pasta-1) or BSA (control) cross-linked beads, and detecting co-precipitating Nef or a Nef molecule with a deletion in the ␣-helix domain, V 10 E⌬17-26, (⌬␣-hx) as described under "Materials and Methods." A titration of wild type Nef adenovirus at MOIs of 200:1, 100:1, and 50:1 were used to ensure equal Nef levels between wild type and mutant. The results were similar in two independent experiments. D, ␤ 2 m is required for co-precipitation of Nef with tapasin in astrocytic cells (373mg). 373mg cells were transfected with the indicated siRNA, transduced with an adenovirus expressing Nef at an MOI of 25:1, and incubated for 48 h. Co-precipitation of Nef and MHC-I with tapasin was assessed by immunoprecipitation with pasta-1 or BSA-cross-linked beads followed by Western blot analysis. The results were similar in two independent experiments. E, ␤ 2 m is required for co-precipitation of Nef and tapasin in CEM T cells. CEM T cells expressing HA-A2 were transduced with an adenovirus expressing Nef at an MOI of 100:1 for 24 h and then transfected with the indicated siRNA as described under "Materials and Methods." Co-precipitation of Nef was then assessed as described for D. The results were similar in two independent experiments. F, Nef co-precipitates with unfolded MHC-I. 373mg cells were transfected with the indicated siRNA, transduced with an adenovirus expressing Nef at an MOI of 25:1, and incubated for 48 h. Co-precipitation of Nef with MHC-I was assessed by immunoprecipitation with HC10 or BB7.2 cross-linked beads followed by Western blot analysis. The results were similar in two independent experiments. duced. For example, the combined effect of temperature reduction and serine to alanine cytoplasmic tail mutations (TM1,2,4) had the greatest impact. Under these conditions there was an increase in the relative effect of Nef from 2.2-to 40-fold. Similar to what we observed in T cells, the hypophosphorylated mutant TM1,2,4 co-precipitated more Nef than wild type HLA-A2 (Fig. 6E) . This is consistent with our model that Nef targets hypophosphorylated forms of MHC-I. However, because TM1,2,4 also affects transport rate in HeLa cells, there may be more than one explanation for how it stimulates Nef activity in this cell type.
It was recently reported that in T cells, Nef binding redirects MHC-I from the TGN to the lysosomes by recruiting AP-1 to the MHC-I cytoplasmic tail (26) . AP-1 is an adaptor protein complex that mediates vesicular transport between the TGN and endolysosomal pathway by linking cargo proteins to clathrin. To determine whether AP-1 might be important for Nef activity in HeLa cells, we used RNA interference to reduce AP-1 expression (Fig. 7A ). Under these conditions the relatively small effect of Nef on steady state MHC-I expression measured flow cytometrically at 37°C was reversed (Fig. 7B) . In addition, the more dramatic effect of Nef observed at lower temperatures was also reversed (Fig. 7B) . Moreover, siRNA to AP-1 reversed the effects of Nef on MHC-I transport (Fig. 7C ) and surface stability (Fig. 7D) . Thus, AP-1 appears to be important for Nef activity in HeLa cells.
To determine whether the rapid rate of MHC-I transport in HeLa cells might limit Nef activity by affecting AP-1 recruitment to the MHC-I cytoplasmic tail, we immunoprecipitated MHC-I from HeLa cells and performed a Western blot to assess Nef and AP-1 co-precipitation. Under normal (37°C) conditions, we were able to detect Nef but not AP-1 in the immunoprecipitates. Interestingly, reducing MHC-I transport rate by temperature reduction dramatically increased the amount of AP-1 but not Nef in the complex (Fig. 7E) .
DISCUSSION
The HIV-1 Nef protein inhibits antigen presentation by reducing cell surface expression of MHC-I. Recent evidence indicates that Nef redirects MHC-I from the TGN to the endolysosomal pathway by recruiting AP-1 to the MHC-I cytoplasmic tail (26) . Here we show that Nef begins to affect MHC-I very early in the secretory pathway while it is in a hypophosphorylated form. First, we demonstrated that Nef preferentially co-precipitated with MHC-I mutants that mimicked hypophosphorylated MHC-I. The results obtained comparing the sensitivity of TM1, TM2, and TM4 to Nef suggest that hypophosphorylation of the region immediately around the Nef-binding site (TM2) had the greatest stimulatory effect. In addition, mutations that mimicked phosphorylation adjacent to the Nef-binding site (TM2E and TM3E) inhibited co-precipitation of Nef. Further evidence that Nef interacts with MHC-I early in the secretory pathway was that Nef co-precipitated with endo H-sensitive MHC-I and with MHC-I bound to the ER chaperone tapasin. Finally, we found that Nef did not co-precipitate with MHC-I that had reached the cell surface. These data indicate that Nef preferentially binds immature MHC-I early in the secretory pathway.
We also found that Nef expression inhibited MHC-I phos- FIG. 6 . HLA-A2 transport affects the ability of Nef to disrupt MHC-I cell surface expression. A, MHC-I is transported more slowly in T cells. Primary T cells expressing endogenous HLA-A2 or CEM T cells and HeLa cells expressing the indicated MHC-I were pulse-labeled, immunoprecipitated, and digested with endo H as described under "Materials and Methods." r denotes endo H-resistant HLA-A2, and s denotes endo H-sensitive HLA-A2. The percentage of endo H-sensitive was calculated as described in Fig. 3A) . The results were similar in two independent experiments. B, reduction of MHC-I maturation rate rescues Nef responsiveness. HeLa cells expressing HLA-A2 or TM1,2,4 were treated with adeno-Nef or control adeno-vector at an MOI of 100:1 on day one. On day 2, one set of samples was shifted to 26°C overnight. After 3 days the cells were harvested, stained for HLA-A2, and analyzed by flow cytometry. Green line, adeno-Nef; red line, adeno-vector. The results were similar in two independent experiments performed in duplicate. C, conditions that enhance the ability of Nef to disrupt MHC-I cell surface expression do not alter MHC-I surface stability. HeLa cells expressing the indicated MHC-I molecule were transduced with adeno-Nef at an MOI of 100:1, and surface stability was measured as previously described (25) . The results were similar in two independent experiments. D, the effect of reducing temperature on HLA-A2 transport. MHC-I transport in HeLa cells transduced with adenoviral vectors at an MOI of 50:1 was measured as described in Fig. 3B . E, mimicking hypophosphorylation of the HLA-A2 cytoplasmic tail enhances co-precipitation of Nef. HeLa cells expressing the indicated MHC-I molecule were transduced with adeno-Nef at an MOI of 50:1, and Nef binding to MHC-I was assessed by Western blot and densitometry as described under "Materials and Methods." c denotes HeLa cells that do not express HLA-A2 used as a control. The results were similar in two independent experiments. phorylation, which normally occurs in a post-TGN compartment (39) . This is consistent with the model that Nef disrupts MHC-I trafficking early in the secretory pathway and diverts MHC-I from the compartment in which it is normally phosphorylated. However, it is also possible that inhibition of phosphorylation is due to Nef physically blocking phosphorylation of the MHC-I cytoplasmic tail. More studies are needed to resolve these two possibilities.
The importance of events early in the secretory pathway was also highlighted by our data comparing MHC-I transport rates in different cell types. We found that HLA-A2 was transported more rapidly through the early secretory compartments of HeLa cells than T cells. Reducing MHC-I maturation rate by temperature reduction augmented the ability of Nef to disrupt MHC-I transport to the cell surface in HeLa cells by increasing the association of AP-1 with the Nef⅐MHC-I complex. Although other explanations are possible, these data suggest that a slower maturation rate may allow the Nef⅐MHC-I complex to spend a longer period of time in part of the secretory compartment where AP-1 can associate.
Our studies also revealed that AP-1 is needed for Nef to destabilize cell surface MHC-I in HeLa cells. More work is needed to determine whether this is due to increased endocytosis or decreased recycling of internalized molecules back to the cell surface.
In addition, more work is needed to fully understand the importance of the MHC-I transport rate in normal MHC-I biology. Interestingly, temperature reduction (which affects MHC-I transport rate) has been shown to increase peptide loading and stability of MHC-I (44). Thus, the slower trafficking of MHC-I that we observed in T cells may allow more time to optimize protein folding. Finally, our discovery that the MHC-I cytoplasmic tail sequences affected MHC-I maturation rate in HeLa cells suggests that under some conditions, the cytoplasmic tail may be involved in regulating MHC-I folding and transport.
Two other viral proteins have been reported to inhibit MHC-I phosphorylation as a result of disrupting antigen presentation. Adenovirus E3/19k causes retention of MHC-I in the ER, and thus MHC-I remains unphosphorylated in cells expressing this protein (40) . The KSHV-K5 protein promotes the endocytosis of MHC-I, and its effect on phosphorylation may be due to the accumulation of MHC-I in recycling endosomes prior to their transport to lysosomes (27) . In neither case has the phosphorylation state of the MHC-I cytoplasmic tail been demonstrated to affect responsiveness to the viral protein. Indeed, mutation of cytoplasmic tail serines to alanines did not affect the ability of KSHV-K5 to disrupt MHC-I trafficking (27) . Thus, this is the first report that mutation of cytoplasmic tail serines can influence the ability of a viral protein to inhibit antigen presentation.
In sum, our data best support the following model for how Nef disrupts MHC-I trafficking in T cells: HIV Nef preferentially binds hypophosphorylated MHC-I early in the secretory pathway. As a result, Nef specifically targets newly synthesized molecules that might harbor viral peptides. Transport of MHC-I to the TGN occurs normally but then MHC-I is retained in the TGN and diverted to lysosomes because of recruitment of AP-1 to the MHC-I cytoplasmic tail (26) . The presence of Nef bound to the cytoplasmic tail (21) or the diversion of MHC-I from the plasma membrane (or both of these events) prevents phosphorylation of MHC-I. These findings have important implications for understanding the molecular mechanism of HIV immune evasion, as well as for understanding normal MHC-I biology.
Acknowledgments-We are grateful to members of the Collins laboratory for helpful suggestions. We thank Dr. Peter Cresswell for pro-FIG. 7. Reducing HLA-A2 transport rate by temperature reduction enhances Nef-dependent recruitment of AP-1 to the HLA-A2 cytoplasmic tail. A, AP-1 and Nef expression levels were assessed in cells treated with RNA interference by Western blot as described under "Materials and Methods." B, AP-1 is required for Nef activity at both 37 and 26°C degrees. HeLa cells transfected with the indicated siRNA were transduced with a control adenovirus (red curve) or an adenovirus expressing Nef (green curve) at an MOI of 50:1 as described under "Materials and Methods." The numbers in the top right-hand corner of each fluorescence-activated cell sorter plot indicate the fold reduction in HLA-A2 cell surface expression. The results were similar in two independent experiments. C, AP-1 is required for Nef to disrupt MHC-I transport in HeLa cells. The cells treated with the indicated siRNA were transduced with adenoviral vectors at an MOI of 50:1, and surface transport was measured as described in Fig. 3B . D, the effect of AP-1 siRNA on Nef-dependent MHC-I surface instability. HeLa cells expressing HLA-A2 were treated with RNA interference as described under "Materials and Methods" and transduced with adeno-Nef at an MOI of 50:1. Surface stability was measured as described for Fig. 6D . E, AP-1 recruitment to the HLA-A2 cytoplasmic tail. HeLa cells transfected with the indicated siRNA were transduced with adenovirus as described for A. Co-precipitation of Nef and AP-1 was assessed by Western blot as described under "Materials and Methods." c denotes HeLa cells that do not express HLA-A2. The results were similar in two independent experiments.
